Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi-Sankyo and ArQule announce partnership

Daiichi-Sankyo and ArQule announce partnership

11th November 2008

Daiichi-Sankyo and ArQule have announced a research and development partnership in a hope to progress novel compounds in order to target cancer.

The two companies hope that the partnership will see the development of ARQ 197, an orally administered and proprietary small molecule inhibitor of the c-Met receptor tyrosine kinase.

In an attempt to develop a new generation of highly selective anti-cancer kinase inhibitors, the partnership will advance the application of ArQule’s kinase inhibitor discovery platform.

Paolo Pucci, chief executive officer of ArQule, said: “We are delighted to welcome Daiichi Sankyo as a partner in our shared quest to bring innovative cancer therapeutics to patients and their physicians.”

He added: “With this announcement, we complete the ARQ 197 partnership process.”

The agreement is set to see a total cash payment of $75 million (48 million pounds) from Daiichi Sankyo to ArQule.

Earlier this week, Daiichi Sankyo reported the results of a new study examining heart attacks.

The research saw non-fatal heart attack patients – who complained of chest pains within the first three months of hospitalisation – had a higher risk of dying or having another attack in the following three to four years.

Daiichi Sankyo was founded by Dr Jyokichi Takamine.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.